Prestige Q3 revenue $274.5M (+14.9% YoY), EPS $0.99 (+22.2%); raises FY22 outlook

Prestige Consumer Healthcare Inc.

2022-Q3 EPS reported $3.02 revenue$819,876,000

Revenue $274.5M, up 14.9% YoY; organic growth 8.8% excluding currency and Akorn acquisition.
Diluted EPS $0.99, up 22.2% YoY; FY22 adjusted diluted EPS guidance raised to $4.00-$4.04.
Non-GAAP free cash flow $64.1M in Q3 vs $43.5M prior year; FY22 free cash flow guidance raised to $250M+.
North America OTC segment $240.9M (+14.4%); International OTC $33.6M (+19.3% record).
Paid down $70M debt in Q3; net debt ~$1.5B, covenant leverage ratio 3.9x.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.